DOCSLIB.ORG

Summary • Editorial June 2017 • In

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Summary • Editorial June 2017 • In Summary • Editorial June 2017 • In memory of Enrico Mihich by Gios Bernardi • 29th Pezcoller Symposium: Abstracts of oral presentations Abstracts of posters • Call for Nomination 2018 Pezcoller Foundation-AACR International Award for Cancer Research • Call for Nomination 2018 Pezcoller Foundation EACR Award • Call for Nomination Scholar-In-Training Awards News from the Year 27 – No. 48 Pezcoller Foundation Word June 2017 June 2017 Editorial Editorial It’s a great pleasure to report that the recipient Function Co-Sustain-Mammary Epithelial Differ- of the 2017 Pezcoller Foundation-AACR Interna- entiation Through Dna Damage Repair” at the tional Award for Cancer Research is David Living- Washington Convention Center during the AACR ston M.D., Emil Frei Professor of Medicine, Har- Annual Meeting. vard Medical School, Boston, MA and Professor Dr. Livingston has presented the Pezcoller Foun- of Genetics, Deputy Director Dana-Farber Can- dation-AACR International Award for Cancer cer Institute, current Chairman of the Pezcoller Research Lecture at the University of Padova, Symposia. hosted by the Department of Molecular Medicine directed by Prof. Stefano Piccolo. The Selection Committee met in Philadelphia He also gave the Pezcoller Foundation-AACR In- on December 5th 2016 and was chaired by Jedd ternational Award for Cancer Research Lecture D. Wolchok, MD, PhD of the Memorial Sloan Ket- at the University of Trento, at the Centre for tering Cancer Institute of New York. The other Integrative Biology directed by Prof. Alessandro members of the Committee were: Donatella del Quattrone. Bufalo, PhD, Senior Researcher Regina Elena Na- Afterwards the award was solemnly given in tional Cancer Institute Rome, Italy; Manel Estell- the prestigious hall of the Buonconsiglio Castle er, MD, PhD, Laboratory Director, Cancer Epige- in Trento on May 5. In this occasion David Liv- netics Group Institute d’Investigació Biomèdica ingston was introduced by the President of the de Bellvitge (IDIBELL), Barcelona, Spain; Judy Pezcoller Foundation Dr. Enzo Galligioni. The Garber, MD, MPH, FAACR, Director Center for ceremony was also attended by dr. Nancy David- Cancer Genetics and Prevention Dana-Farber son, past President of the AACR. Cancer Institute Boston, MA; Mien-Chie Hung, PhD, VP for Basic Research, Professor and Chair Gios Bernardi M.D. Department of Molecular & Cell Oncology, UT Editor and President Emeritus MD Anderson Cancer Center Houston, TX; Karen Knudsen, PhD Director Thomas Jefferson Univer- sity Sidney, Kimmel Cancer Center, Philadelphia, PA; Daniel S. Peeper, PhD, Professor of Function- al Oncogenomics Netherlands Cancer Institute, Amsterdam, Netherlands; Stefan M. Pfister, MD Professor Division of Pediatric Neurooncology, German Cancer Research Center, Heidelberg, Germany. Dr. Livingston’s work has been pivotal to our un- derstanding of the retinoblastoma pathway of cell cycle control as well as the transcriptional co-activation function of the key regulatory pro- teins, p300 and CBP. Furthermore, he is credit- ed with the landmark discovery of the central functions of the tumor suppressors, BRCA1 and BRCA2, which has revolutionized the fields of breast and ovarian cancer research. Dr. Living- ston is lauded by his colleagues as the founder of a wide range of scientific fields, far beyond the realm of cancer research. Dr. Livingston’s tremendous reputation as a re- Picture on front page: spected and admired scientist, colleague, and 2017 Pezcoller Foundation-AACR International mentor is evident through his continued impact Award for Cancer Research in the Main Hall of on the scientific endeavor. the Buonconsiglio Castle, Trento Dr. Livingston has presented the Pezcoller Lec- From the left: Enzo Galligioni , President – David ture, “Brca1, Other Fanconi-Gene, And Swi/Snf Livingston, winner – Nancy Davidson, AACR The Pezcoller Foundation Journal - June 2017 3 In memory of Enrico Mihich by Gios Bernardi Memorial Enrico Mihich MD, true friend and fundamen- Pezcoller Foundation for almost thirty years. tal support for Pezcoller Foundation, died De- Together with the Foundation’s presidency, he cember 29, 2016 at the age of 88, in Boston MA. was the architect of the fundamental agree- Mihich was born in Fiume (Rijeka) in 1928. ment between Pezcoller and AACR to estab- He graduated from the University of Milan in lish the Pezcoller Foundation-AACR Interna- 1951 and then moved to the Sloan Kettering tional Award for Cancer Research in 1997, a Cancer Center, in New York City, in 1952. partnership that continues today. He was the He joined Roswell Park Cancer Institute in inventor and initiator of the Pezcoller Sympo- 1957 and from 1969 to 2006 he was Chair sia, and served as chairman of the Pezcoller of the Molecular Pharmacology and Cancer Symposium Committee until 2008 and since Therapy Program at the Buffalo University. then together with David Livingston. Every Starting from 1984, he served six years as year he took part also in the Symposia Stand- a member of the NIC, National Institute of ing Committees. Cancer. Despite the more than evident difficulties, he Dr. Mihich retired from Roswell Park in 2007, continued to participate in all our symposia, moved to Brookline, MA, and joined the while this year, on the occasion of the 29th Dana Farber Cancer Institute as a Presidential Symposium, he will not be with us and we will Scholar, serving as a special assistant to the surely miss him. president for sponsored research. The Board of Pezcoller Foundation, with its He published more than 400 scientific papers President Galligioni and myself, would like to and worked in the editorial boards of prestig- extend our heartfelt condolences to his wife ious peer-reviewed journals. Marisa, his daughter Sylvia and his grand- He was a true friend and partner of the daughters. Picture: dr. Enrico Mihich, 2010 4 The Pezcoller Foundation Journal - June 2017 29th Pezcoller Symposium Building New Bridges Between Basic and Cancer Science Trento, Italy, June 22-23, 2017 Symposium FOCUS AND GOAL Th is issue of our Journal is dedicated to the 29th of more precise and, hence, eff ective therapy Pezcoller Symposium entitled “Building New for individual patients. Th ese major advanc- Bridges Between Basic and Cancer Science” to es, notwithstanding, cure still remains elu- be held in Trento from June 22 to June 23, co- sive, especially for advanced and particularly chaired by David Livingston, Alberto Bardelli, aggressive cancers. One major reason is that Massimo Loda and Stefano Piccolo. the basic scientifi c forces that drive cancer de- Th is Symposium will focus on a growing set of velopment, establish its aggressive and some- observations in the cancer fi eld and their im- times lethal nature, and wall it off from im- plications for the future. Th e past decade has munological killing remain incompletely or witnessed the development and application of poorly understood. Th us, without the growth groundbreaking technologies that have im- of new, basic cancer science knowledge, fre- proved cancer diagnosis, prognosis making, quent cures of most advanced or aggressive and therapy. As a result, the outlook for cancer cancers will be diffi cult to achieve. Hence, this patients has brightened. Chief among these Symposium aims to defi ne the limits of our new approaches are a strong and productive understanding of the basic biology of cancer thrust towards the discovery and development cells and of the cells of the tumor microen- of powerful targeted agents for cancer thera- vironment in which cancers arise and prolif- py; the discovery and development of novel, erate. It will also propose and describe new immunologically-directed therapies that have opportunities for moving beyond these limits. led to extraordinarily positive therapeutic ef- In essence, this meeting has been built upon fects in certain cancer patients; and the grow- the premise that ongoing progress in these en- ing value of deciphering the sequences of can- deavors will be needed to achieve ever better cer genomes and its contribution to the design cancer therapy and prevention. 5 29th Pezcoller Symposium BUILDING NEW BRIDGES BETWEEN BASIC AND CANCER SCIENCE Trento, Italy • June 22 - 23, 2017 PROGRAM THURSDAY JUNE 22, 2017 FRIDAY, JUNE 23, 2017 8.00 Registration Session I, part 3 The Roots of Cancer (continues) 8.35 Enzo Galligioni Welcome Chair/Moderator: Stefano Piccolo 8.45 David Livingston Focus & Goals 08.00 Gioacchino Natoli 08.55 The Enrico Mihich Lecture Transcriptional Control of Differentiation in Cancer Cells Robert Weinberg 08.25 Discussion Mechanisms of Malignant Progression 08.40 Valerie Weaver Tissue Tension Reprograms the Tumor Session I, part 1 The Roots of Cancer 09.05 Discussion Chair/Moderator: Pier Giuseppe Pelicci Session II, Frontiers of Immunological 09.40 Gerard Evan and Therapeutics Science Targeting the Engines of Cancer, not the Drivers Chair/Moderator: Alberto Bardelli 10.05 Discussion 09.20 Robert Schreiber 10.20 Alan D’Andrea Personalizing Cancer Immunotherapy PARP Inhibitor Resistance and Acquired Vulnerability in Ovar- 09.45 Discussion ian Cancer 10.00 Laurie Glimcher 10.45 Discussion Stressed out: A Novel Approach to Cancer Immunotherapy 11.00 Fabrizio D’Adda di Fagagna 10.25 Discussion DNA Damage Response in Cancer and the Role of non coding RNA 10.40 Coffee Break 11.25 Discussion 10.50 Giulio Draetta 11.40 Coffee Break Targeting Critical Dependencies in Pancreatic Cancer 11:50 Pier Giuseppe Pelicci 11.15 Discussion Biological Heterogeneity of Tumors 11.30
Load more

Recommended publications
  • Special Edition Inside
    A Publication by The American Society for the Pharmacology and Experimental Therapeutics Pharmacologist Inside: Feature articles from 2014-2015 Special Edition VISIT THE ASPET CAREER CENTER TODAY! WWW.ASPET.ORG/CAREERCENTER/ 4 5 12 21 30 41 WHAT YOU NEED: ASPET’S CAREER CENTER HAS IT 52 Jobseekers: Employers: No registration fee Searchable résumé database Advanced search options Hassle-free posting; online account management tools 61 Sign up for automatic email notifi cations of new jobs that Reach ASPET’s Twitter followers (over 1,000), match your criteria LinkedIn Members (over 2,000), and email subscribers (over 4,000) Free & confi dential résumé posting 71 Post to just ASPET or to entire NHCN network Access to jobs posted on the National Healthcare Career Network (NHCN) Sign up for automatic email notifications of new résumés that match your criteria Career management resources including career tips, coaching, résumé writing, online profi le development, Job activity tracking and much more ASPET is committed to your success: The ASPET Career Center is the best resource for matching job seekers and employers in the pharmacology and related health science fi elds. Our vast range of resources and tools will help you look for jobs, fi nd great employees, and proactively manage 9650 Rockville Pike, Bethesda, MD 20814-3995 your career goals. Main Office: 301.634.7060 www.aspet.org ASPET Career Center Full Page Ad 2015 Updated.indd 1 1/15/2016 3:18:16 PM The Pharmacologist is published and distributed by the American Society for Pharmacology and Experimental Therapeutics. THE PHARMACOLOGIST VISIT THE ASPET CAREER CENTER TODAY! PRODUCTION TEAM Rich Dodenhoff Catherine Fry, PhD WWW.ASPET.ORG/CAREERCENTER/ Judith A.
    [Show full text]
  • Speaker Bios
    Moores UCSD Cancer Center Industry/Academia Translational Oncology Symposium Speaker Bios David R. Bentley, D.Phil. Vice President & Chief Scientist, Illumina, Inc. David Bentley, Ph.D., is Chief Scientist for Illumina’s Sequencing business. His major research interest is the study of human sequence variation. He was previously Head of Human Genetics and founding member of the Board of Management at the Wellcome Trust Sanger Institute where he played leading roles in the Institute’s contribution to the human genome referencing sequence, the SNP Consortium and the International HapMap Project. Dr. Bentley earned a degree in Natural Sciences from the University of Cambridge, took a DPhil at the University of Oxford, and is currently a Fellow of the Academy of Medical Sciences. Clara D. Bloomfield, M.D. Distinguished University Professor William G. Pace III Professor of Cancer Research Cancer Scholar and Senior Advisor, Ohio State University Comprehensive Cancer Center and James Cancer Hospital and Solove Research Institute Education &Academic Appointments: 1968 M.D. U Chicago; 1973-80, Assistant, Associate Prof. of Medicine, U Minnesota (U. MN), Minneapolis, MN; 1980-89 Prof. of Medicine, Div. of Oncology, U.MN; 1989-97 Prof. of Medicine & Chief, Div. of Oncology, State University of NY at Buffalo; 1989-97 Chair, Department of Medicine, Roswell Park Cancer Institute (RPCI), Buffalo, NY; 1997-2001 Director, Div. of Hematology & Oncology, Department of Internal Medicine, The Ohio State University College of Medicine & Public Health (OSU COMPH), Columbus, OH; 1997- William G. Pace III Endowed Chair in Cancer Research & Prof, OSU; 1997-2003 Director, Comprehensive Cancer Center (CCC) & Deputy Director, James Cancer Hospital & Solove Research Institute (JCH), OSU; 2003- Cancer Scholar & Senior Advisor, OSUCCC & JCH; 2006- Distinguished University Prof.
    [Show full text]
  • Appendix 1*) for Essential Information Very Well Illustrated in Google and Wikipedia
    Appendix 1*) For Essential Information Very Well Illustrated in Google and Wikipedia *) in Support of the Text with Literature Citations. Referrals to illustrations in Appendix 2. Cancer in the Plant. The insertion of the Agrobacterium tumefaciens circular plasmid T (transferred) DNA into the genome of its new host, the plant (Gelvin BS. Microbiol Molecular Biol Rev 2003;67:16–37). The plant cancer “crown gall” (agrocallus; Agrobacterial crown gall) consists of malignantly transformed cells replicating the agrobacterial T DNA plasmid (reviewed in postscript Table XXXV). For reference: Koncz C Mayerhofer R Koncz-Kálmán Zs et al EMBO J 1990;9:1337–1346. Transfer of potentially oncogenic bacterial genes and proteins to patients: Septicemic Bacteroides enterotoxigenic (Sinkovics J G & Smith JP Cancer 1970;25:663–671; Viljoen KS et al PLoS One 2015;10(3):e0119462); Bartonella bacilliformis etc (Guy L et al PLoS Genet 2013;9(3):e1003393; Harms A & Dehio C Clin Microbiol Rev 2012;25:42–78; Llosa M et al Trends Microbiol 2012;20:355–9; Minnick MF et al PLoS Negl Trop Dis 2014;6(7):e2919); Helicobacter pylori (Bonsor DA et al J Biol Chem 2015;pii:jbc.M115.641829; Su YL et al J Immunol 2015;194:3997–4007; Vaziri F et al Pathog Dis 2015;73(3). pii.ftu021); Porphyromonas gingivalis (Katz J et al Int J Oral Sci 2011;3:209–215); Tuberculous infections with A. tumefaciens in patients (Ramirez FC et al Clin Infect Dis 1992;15:938–940). DNA-binding Antibodies. DNA- (or RNA-) binding proteins use zink finger motifs, leucine zippers and winged (beta-sheet loops) helix-turn helix motifs (HTH, two helices separated by the loop, RNA/DNA-binding domains) in recognition of RNA/DNA receptors for attachment.
    [Show full text]
  • Emil Frei III, MD: in Memoriam (1924–2013)
    Cancer Obituary Research Emil Frei III, MD: In Memoriam (1924–2013) "Tackle a big problem and stay with it"—advice from Emil Frei II to Emil Frei III Emil Frei III (Tom) was probably the most admired Amer- pleura-pneumonia–like organism. They worked out the nature ican cancer researcher of his generation. His death marks the of the infection in the ear canal of the rat and how to cure it with end of an amazing journey in oncology, a field that was in its a new antibiotic, tetracycline. Tom credited this and subsequent infancy in February 1955 when he arrived at the National experience with Dr. Zubrod (after both had moved to NCI) with Cancer Institute (NCI; Bethesda, MD). During his long career, teaching him about rigorous measurement in clinical research he contributed importantly to the cure of childhood leukemia, and the importance of the laboratory in bringing science to the Hodgkin's disease and other lymphomas, breast cancer, and bedside. other malignancies. It would be appropriate to state that his When Tom arrived at the NCI in 1955 at the age of 31 years, he work and that of his colleagues' has saved and will save millions decided to focus on the treatment of leukemia. Quantitative of lives throughout the world. Born in St. Louis, Tom Frei grew studies on leukemia were lacking; the relative response rates up in a deeply religious family, surrounded by artists and to two known chemotherapeutic agents, methotrexate and musicians. The family business was the Emil Frei Art Glass 6-mercaptopurine, were unknown; and no one had defined Company, founded by his grandfather and managed by his partial and complete responses.
    [Show full text]
  • October 2, 2020 | 8:30 A.M.—5:30 P.M
    in Tumor Immunology and Cancer Immunotherapy Conference October 2, 2020 | 8:30 a.m.—5:30 p.m. Time Title Speaker Neli Ulrich, PhD 8:30 a.m. Welcome Executive Director, Comprehensive Cancer Center Huntsman Cancer Institute Antitumor Immune Responses Induced by PD-1 Antoni Ribas, MD, PhD 8:45 a.m. Blockade Therapy University of California Los Angeles Rational Tumor and Immune Cell Treatment Daniel Peeper, PhD 9:30 a.m. Combinations: A Functional Genomics Approach Netherlands Cancer Institute 10:15 a.m. Break Sandra D’Angelo, MD 10:30 a.m. Cancer Testis Antigens as Therapeutic Targets in Sarcoma Memorial Sloan Kettering Cancer Center New T Cell Receptors and Targets by Dissection of Andrew Sewell, PhD 11:15 a.m. Successful Cancer Immunotherapy Cardiff University Noon Lunch CAR T Cell-Based Combination Immunotherapy for Prasad S. Adusumilli, MD, FACS 1 p.m. Solid Tumors Memorial Sloan Kettering Cancer Center Overcoming Resistance to Immune Checkpoint Blockers Zihai Li, MD, PhD 1:45 p.m. by Targeting GARP-TGF-Beta Pathway The Ohio State University 2:30 p.m. Break From the Clinic to the Lab: Investigating Mechanisms of Padmanee Sharma, MD, PhD 2:45 p.m. Response and Resistance to Immune Checkpoint Therapy MD Anderson Cancer Center The Role of Gut and Tumor Microbiome in Response Jennifer Wargo, MD, MMSc 3:30 p.m. to Cancer Therapy MD Anderson Cancer Center 4:15 p.m. Break Ira Mellman, PhD 4:30 p.m. Mechanistic Basis of Cancer Immunotherapy Genetech Alana Welm, PhD 5:15 p.m. Closing Remarks Co-Director, Cell Response and Regulation Program Huntsman Cancer Institute SPEAKERS Prasad S.
    [Show full text]
  • AACR Settles Dispute with Toronto Hotels Over 2003 Annual Meeting
    Vol. 31 No. 15 April 15, 2005 © Copyright 2005 The Cancer Letter Inc. All rights reserved. Price $335 Per Year AACR Settles Dispute With Toronto Hotels Over 2003 Annual Meeting Cancellation By Kirsten Boyd Goldberg The American Association for Cancer Research has settled a legal dispute with the Toronto Convention Center and hotels, stemming from the AACR 2003 Aftermath: cancellation of its annual meeting in April 2003. NCI Provided $2 Million The convention center and 19 hotels sought $6.2 million Canadian To Pay Washington from AACR as payment under contracts for housing the estimated 16,000 Convention Center, scientists and others who were expected to attend the meeting. Other Expenses Two days before the event was scheduled to begin, AACR cancelled . Page 2 it, citing the outbreak of Severe Acute Respiratory Syndrome in Toronto. (Continued to page 2) Washington Roundup: In Brief: Senate Committee AACR To Honor Eight Scientists Delays Session At Annual Meeting In Anaheim On FDA Nominee The American Association for Cancer Research will honor several . Page 4 scientists at its annual meeting April 16-20, in Anaheim, Calif. David Livingston, deputy director, Dana-Farber/Harvard Cancer Center National Academies: and the Emil Frei Professor of Genetics and Medicine, Harvard Medical Report Defines School, will receive the AACR-G.H.A. Clowes Memorial Award for his Indicators Of Progress contributions to the understanding of the molecular basis of cancer. In Quality of Care Charles Sawyers, investigator, Howard Hughes Medical Institute and . Page 5 Peter Bing Professor of Medicine, University of California, Los Angeles, will be awarded the AACR-Richard and Hinda Rosenthal Foundation Award Oversight Needed for his research in molecularly-targeted therapy, with special emphasis on For Cord Blood Banks, signaling pathway abnormalities in cancer cells as targets for drug therapy.
    [Show full text]
  • A Tribute to Emil Frei III
    Obituary A tribute to Emil Frei III Dr. Emil Frei III, one of the fathers of be found) was opposed by Abraham Goldin combination chemotherapy for cancer, and Lloyd Law at the NCI as well as Howard died after a prolonged illness in May of Skipper and Frank Schabel at the Southern 2013. He was 89 years old (Figure 1). Research Institute in Alabama, who were Known to his colleagues, family, and experts in the drug treatment of leukemic friends as Tom, Frei was the emeritus cell lines and murine leukemia. They held director and emeritus physician-in-chief that combinations of drugs with different of the Dana-Farber Cancer Institute and targets given simultaneously provided the the Richard and Susan Smith Distin- only hope for sustained remissions, since guished Professor of Medicine emeritus most cancers have infinite ways of finding at Harvard Medical School. A highly dis- their way around single agents. Zubrod, tinguished clinical investigator, Frei held whose military medicine experience was in leadership positions of major responsibil- the malaria program of World War II, saw ity at the National Cancer Institute (NCI) childhood leukemia as the cancer equiva- in Bethesda, Maryland, and at the M.D. lent of malaria and agreed with the basic Anderson Cancer Center in Houston, scientists. He urged Frei and Freireich to Texas, before his appointment at Harvard. combine drugs as they were produced to Frei was born in St. Louis on February 21, treat leukemia in childhood, to collaborate 1924, where his paternal grandfather had with other like-minded physicians, and to founded Emil Frei and Associates, a well- train younger physicians to learn the new known stained glass company.
    [Show full text]
  • A History of Cancer Chemotherapy Vincent T
    AACR Centennial Series A History of Cancer Chemotherapy Vincent T. DeVita, Jr. and Edward Chu Yale Cancer Center, Yale University School of Medicine, New Haven Connecticut Abstract The Early Period of Cancer Drug Development The use of chemotherapy to treat cancer began at the start of A selected history and timeline of events related to the the 20th century with attempts to narrow the universe of development of cancer chemotherapy is shown in Fig. 1. The first chemicals that might affect the disease by developing methods four decades of the 20th century were primarily devoted to model to screen chemicals using transplantable tumors in rodents. development. The major limitations of drug discovery were two- It was, however, four World War II–related programs, and the fold: first, the development of models that could effectively be used effects of drugs that evolved from them, that provided the to reduce the vast repertoire of chemicals to those few that might impetus to establish in 1955 the national drug development have activity against cancer in humans, and second, the access to effort known as the Cancer Chemotherapy National Service clinical facilities to test such agents. Center. The ability of combination chemotherapy to cure acute A major breakthrough in model development occurred in the early childhood leukemia and advanced Hodgkin’s disease in the 1910s when George Clowes of Roswell Park Memorial Institute (RPMI) 1960s and early 1970s overcame the prevailing pessimism about in Buffalo, New York, Roswell Park Memorial Institute developed the the ability of drugs to cure advanced cancers, facilitated the first transplantable tumor systems in rodents.
    [Show full text]
  • Emil Frei III, MD: in Memoriam (1924–2013)
    Cancer Obituary Research Emil Frei III, MD: In Memoriam (1924–2013) "Tackle a big problem and stay with it"—advice from Emil Frei II to Emil Frei III Emil Frei III (Tom) was probably the most admired Amer- pleura-pneumonia–like organism. They worked out the nature ican cancer researcher of his generation. His death marks the of the infection in the ear canal of the rat and how to cure it with end of an amazing journey in oncology, a field that was in its a new antibiotic, tetracycline. Tom credited this and subsequent infancy in February 1955 when he arrived at the National experience with Dr. Zubrod (after both had moved to NCI) with Cancer Institute (NCI; Bethesda, MD). During his long career, teaching him about rigorous measurement in clinical research he contributed importantly to the cure of childhood leukemia, and the importance of the laboratory in bringing science to the Hodgkin's disease and other lymphomas, breast cancer, and bedside. other malignancies. It would be appropriate to state that his When Tom arrived at the NCI in 1955 at the age of 31 years, he work and that of his colleagues' has saved and will save millions decided to focus on the treatment of leukemia. Quantitative of lives throughout the world. Born in St. Louis, Tom Frei grew studies on leukemia were lacking; the relative response rates up in a deeply religious family, surrounded by artists and to two known chemotherapeutic agents, methotrexate and musicians. The family business was the Emil Frei Art Glass 6-mercaptopurine, were unknown; and no one had defined Company, founded by his grandfather and managed by his partial and complete responses.
    [Show full text]
  • Emil Freireich, MD
    Emil Freireich, MD Session 1—October 5, 2011 About transcription and the transcript This interview had been transcribed according to oral history best practices to preserve the conversational quality of spoken language (rather than editing it to written standards). The interview subject has been given the opportunity to review the transcript and make changes: any substantial departures from the audio file are indicated with brackets [ ]. In addition, the Archives may have redacted portions of the transcript and audio file in compliance with HIPAA and/or interview subject requests. The views expressed in this interview are solely the perspective of the interview subject. They are not to be interpreted as the official view of any other individual or of The University of Texas MD Anderson Cancer Center. Chapter 00A Interview Identifier Tacey Ann Rosolowski, PhD 0:00:10.6 I am Tacey Ann Rosolowski, interviewing Dr. Emil J Freireich. It’s Emil, correct? Emil J Freireich, MD 0:00:17.8 Americans say “ee.” Tacey Ann Rosolowski, PhD 0:00:21.7 How would you like me to say it? Emil J Freireich, MD 0:00:23.1 J. 1 Interview Session: 01 Interview Date: October 5, 2011 Tacey Ann Rosolowski, PhD 0:00:23.4 J Freireich at the University of Texas MD Anderson Cancer Center in Houston, Texas. This interview is being conducted for the Making Cancer History Voices Oral History Project, run by the Historical Resources Center at MD Anderson. Dr. Freireich holds the Ruth Harriet Ainsworth Chair in Developmental Therapeutics. He is also a distinguished teaching professor and director of special medical education programs as well as the director of the Adult Leukemia Research Program at the University of Texas MD Anderson Cancer Center.
    [Show full text]
  • A Tribute to Emil Frei III
    A tribute to Emil Frei III Edward J. Benz Jr., David G. Nathan J Clin Invest. 2013;123(8):3188-3189. https://doi.org/10.1172/JCI71579. Obituary Dr. Emil Frei III, one of the fathers of combination chemotherapy for cancer, died after a prolonged illness in May of 2013. He was 89 years old (Figure 1). Known to his colleagues, family, and friends as Tom, Frei was the emeritus director and emeritus physician-in-chief of the Dana-Farber Cancer Institute and the Richard and Susan Smith Distinguished Professor of Medicine emeritus at Harvard Medical School. A highly distinguished clinical investigator, Frei held leadership positions of major responsibility at the National Cancer Institute (NCI) in Bethesda, Maryland, and at the M.D. Anderson Cancer Center in Houston, Texas, before his appointment at Harvard. Frei was born in St. Louis on February 21, 1924, where his paternal grandfather had founded Emil Frei and Associates, a well-known stained glass company. He attended St. Louis University and then joined the United States Navy in World War II. The Navy sent him to Colgate University and then to Yale University for medical training. He graduated from Yale Medical School in 1948 and later served in the Navy Medical Corps during the Korean War. In 1955, Frei and his close colleague Emil J. Freireich were recruited to the expanding clinical program at the NCI by Gordon Zubrod, then the newly appointed NCI clinical director. Supported by Zubrod’s superb guidance and defense, Frei and Freireich began their […] Find the latest version: https://jci.me/71579/pdf Obituary A tribute to Emil Frei III Dr.
    [Show full text]
  • Emil J. Freireich: Legend in Cancer Research (March 16, 1927–February 1, 2021)
    Bone Marrow Transplantation (2021) 56:1764–1767 https://doi.org/10.1038/s41409-021-01284-z OBITUARY Emil J. Freireich: Legend in cancer research (March 16, 1927–February 1, 2021) Hagop Kantarjian 1 Received: 1 March 2021 / Revised: 3 March 2021 / Accepted: 24 March 2021 / Published online: 13 May 2021 © The Author(s), under exclusive licence to Springer Nature Limited 2021 Emil J. Freireich was a trailblazing scientist and the founding father of modern cancer research and care. To many of us who knew him well, he was much more: an idol and hero, a daily inspirational role model, a mentor and often a third parent. As he did for hundreds of us, Freireich brought me from a distant country to the United States when I was a 24-year-old medical student for a 4-month elective rotation, then in 1981 as a fellow. He took us under his wing 1234567890();,: 1234567890();,: at the University of Texas MD Anderson Cancer Center, provided us with endless opportunities, and helped us become, for better or for worse, who we are today. President Obama’s book title “The Audacity of Hope” describes the two salient characteristics that define the arc of his life and career. Freireich was first and foremost infinitely hopeful and optimistic. He said: “Humans cannot live without hope. Hopelessness is the greatest trauma a person has to suffer.” He knew this firsthand, having been born in 1927 under merciless conditions in Chicago, and having lost his father when he was 2. In his 1997 oral history (preserved at the National Cancer Institute [NCI]), he said, “People born in that era are a special brand of people because they lived through one of the greatest economic dislocations in the history of our species—the Great Depression of 1929….
    [Show full text]